About: Béatrice Mahé

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Béatrice Mahé - Bailliez Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Mahé - Bailliez, Béatrice (1959-....)
alternative label	Bailliez, Béatrice Mahé Mahé, Béatrice Bailliez
Life Event	http://www.idref.fr/188464786/birth
preferred label	Mahé - Bailliez, Béatrice (1959-....)
name	Béatrice Mahé - Bailliez
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
Given name	Béatrice
familyName	Mahé - Bailliez
note	Docteur en médecine (en 1985)
gender	female
is sameAs of	Mahé - Bailliez, Béatrice (1959-....) Mahé - Bailliez, Béatrice (1959-....) Mahé - Bailliez, Béatrice (1959-....) Mahé - Bailliez, Béatrice (1959-....) Mahé - Bailliez, Béatrice (1959-....)
is Author of	http://www.sudoc.fr/042350816/id Prognostic value of interim FDG PET/CT in Hodgkin's lymphoma patients treated with interim response-adapted strategy: comparison of International Harmonization Project (IHP), Gallamini and London criteria. Low number of KIR ligands in lymphoma patients favors a good rituximab-dependent NK cell response Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience Central nervous system involvement by malignant cells is a rare complication of Waldenström macroglobulinemia, and this clinicopathological entity is referred to as the Bing-Neel syndrome. There is currently no consensus on the diagnostic criteria, therapeutic approaches and response evaluation for this syndrome. In this series, we retrospectively analyzed 44 French patients with Bing-Neel syndrome. Bing-Neel syndrome was the first manifestation of Waldenström macroglobulinemia in 36% of patients. When Waldenström macroglobulinemia was diagnosed prior to Bing-Neel syndrome, the median time interval between this diagnosis and the onset of Bing-Neel syndrome was 8.9 years. This study highlights the possibility of the occurrence of Bing-Neel syndrome without any other evidence of progression of Waldenström macroglobulinemia. The clinical presentation was heterogeneous without any specific signs or symptoms. Biologically, the median lymphocyte count in the cerebrospinal fluid was 31/mm(3). Magnetic resonance imaging revealed abnormalities in 78% of the cases. The overall response rate after first-line treatment was 70%, and the overall survival rate after the diagnosis of Bing-Neel syndrome was 71% at 5 years. Altogether, these results suggest that Bing-Neel syndrome should be considered in the context of any unexplained neurological symptoms associated with Waldenström macroglobulinemia. The diagnostic approach should be based on cerebrospinal fluid analysis and magnetic resonance imaging of the brain and spinal axis. It still remains difficult to establish treatment recommendations or prognostic factors in the absence of large-scale, prospective, observational studies. Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity. FLT3 ligand plasma levels in acute myeloid leukemia Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation Interest of a third dose of BNT162b2 anti‐SARS‐CoV‐2 messenger RNA vaccine after allotransplant https://serval.unil.ch/notice/serval:BIB_F0F61F73F24E#id Fms-like Tyrosine Kinase 3 Ligand Concentration Kinetic Profile during Induction Is Strongly Predictive of Survivals in AML: Results of the FLAM/Flal Study Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study. A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia RASmutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiplemyeloma patient harboring BRAF mutation Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients Safety and antibody response after one and/or two doses of BNT162b2 Anti‐SARS‐CoV‐2 mRNA vaccine in patients treated by CAR T cells therapy Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14) A new cytokine‐based dynamic stratification during induction is highly predictive of survivals in acute myeloid leukemia Progression of disease within 2 years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life Autologous stem-cell collection following VTD or VRD induction therapy in multiple myeloma: a single-center experience Biological differences between two commercial anti-CD19 CAR T cells products and impact on outcomes in lymphoma patients.
is primary topic of	http://www.idref.fr/188464786
is Opponent of	http://www.sudoc.fr/250942313/id http://www.sudoc.fr/250942380/id Intérêt pronostique de la POD24 (progression de la maladie dans les 2 ans) dans le lymphome folliculaire, étude monocentrique et rétrospective

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software